This case report describes a 54-year-old man with bipolar I disorder who was treated with aripiprazole (ARP) and lithium. The patient was admitted to our hospital because of aggravation of depressive symptoms, and treatment with lamotrigine (LTG) was initiated. Two weeks after admission, we discontinued administration of ARP after the appearance of a tremor. Three weeks after discontinuing ARP, the patient developed a high fever, rigidity of the arms, diarrhea, dysphagia, and diaphoresis. We suspected these symptoms were consistent with neuroleptic malignant syndrome and therefore removed the application of LTG. After 2 days, most of the patient's symptoms and blood results had improved, leading us to conclude that the LTG treatment had induced neuroleptic malignant syndrome. Thus, the purpose of this case report was to warn psychiatrists against therapy with LTG, as it may be conducive to neuroleptic malignant syndrome.
N euroleptic malignant syndrome (NMS) occurs in approximately 0.1% of hospitalized patients treated with antipsychotics and represents a potentially life-threatening neurological emergency. 1 Neuroleptic malignant syndrome is characterized by fever, rigidity, and alterations in consciousness, and it is often associated with elevated creatine phosphokinase (CPK) levels and leukocytosis. [2] [3] [4] Lamotrigine (LTG) is an effective anticonvulsant that has also demonstrated efficacy in the treatment of mood disorders, particularly bipolar disorder. We offer this report of a patient who developed fever, generalized rigidity, and increased CPK levels following an increase in the dosage of LTG.
CASE REPORT
A 54-year-old man with bipolar I disorder was admitted to our psychiatric hospital because of the exacerbation of depressive symptoms. The patient presented with an 8-year history of bipolar I disorder but had neither a prior history of substance use nor any systemic illness. He had been treated with several antipsychotics in the past without any development of NMS.
Upon admission, the patient was treated with aripiprazole (ARP; 6 mg/d) and lithium (Li; 400 mg/d). Subsequently, a 50-mg/d dose of LTG was added, and this dosage was increased by 50 mg/wk. Two weeks after admission, we discontinued ARP because of the development of a tremor. At the same time, treatment with sertraline (SER; 25 mg) was initiated because of continued symptoms of depression. Five weeks after admission, at which time the patient was receiving LTG at 200 mg/d, Li at 400 mg/d, and SER at 25 mg/d, he developed a fever of 39.1°C with rigidity of the arms, diarrhea, dysphagia, and diaphoresis; rash was not observed. A heart rate of 100 to 120 beats/min, blood pressure of 140/100 mm Hg, and diaphoresis were observed during the physical examination. Laboratory tests indicated the levels of white blood cells at 6000/μL, CPK at 4000 IU/L, alanine aminotransferase (AST) at 121 IU/L, and C-reactive protein at 0.17 mg/L. A neurological examination ruled out a possible brain infection, inflammation, or malignancy, which led us to suspect NMS in this patient. However, because neuroleptics had not been used in the prior 3 weeks, we did not immediately identify a causative agent for NMS. Rather than change prescriptions, we started a drip infusion of Ringer's solution. Unfortunately, the patient's symptoms continued to persist for the next 2 days, with values for CPK peaking at 12,000 IU/L, white cells at 9000/μL, AST at 161 IU/L, and C-reactive protein at 0.33 mg/L. At that point, we suspected that LTG had induced NMS and discontinued the LTG treatment, while leaving the other prescriptions unchanged. After discontinuing LTG, we observed that the majority of the symptoms, including the extrapyramidal signs, improved within 2 days. The fever gradually receded until the patient reached a normal temperature 3 days later. During this period, laboratory tests revealed levels of white blood cells at 6800/μL, CPK at 1200 IU/L, AST at 58 IU/L, and C-reactive protein at 0.13 mg/L. We confirmed the normalization of the majority of these blood parameters 1 week later, and the signs of infection were no longer observed at this point. Two weeks after recovery, the patient was treated with electroconvulsive therapy, which was effective at abating his depressive symptoms.
DISCUSSION
To our knowledge, this is the first reported case of NMS induced by LTG. Based on the diagnostic criteria for NMS outlined by Pope et al, 5 we believe that our patient developed this syndrome because his episode presented all 3 major manifestations, including hyperthermia (>37.5°C), severe extrapyramidal effects (rigidity, diarrhea, and dysphagia), and symptoms of the autonomous nervous system (tachycardia and diaphoresis). Lamotrigine is the most likely causal agent of NMS in this patient because the patient was treated with Li and SER after the initial NMS symptoms, and no further NMS symptoms occurred, although the spontaneous occurrence of an NMS-like syndrome cannot entirely be ruled out.
Several drugs are known to be implicated in the onset of NMS. In a review of the literature, we found more than 20 different compounds to be associated with NMS, particularly firstgeneration antipsychotics and atypical antipsychotics ( Table 1) . Several other classes of drugs with dopamine-blocking pharmacologic effects (eg, amoxapine and metoclopramide) may also cause NMS symptoms. However, it is known that LTG does not directly affect the dopaminergic system 8 ; instead, LTG blocks sodium channels and inhibits the release of glutamate and aspartate, along with inhibiting acetylcholine and γ-aminobutyric acid (GABA) release. 9 Lamotrigine is also known to serve as a weak blocker of T-type calcium channels.
We hypothesize that the GABA-associated properties of LTG may have been responsible for the NMS observed in our patient. Although the exact mechanism for how NMS is associated with the GABAergic system is not yet completely understood, it is known that the GABAergic medication bacrofen may cause symptoms of NMS. 10 Of course we cannot exclude the possibility that this patient's NMS was induced by ARP. However, 3 weeks elapsed after halting the prescription for ARP before the NMS symptoms developed. According to most case reports, 11, 12 NMS typically occurs within 1 week of either an initiation, increase, or interruption of ARP treatment. In particular, initiations and increases are responsible for most cases of NMS. A literature search for NMS caused by the withdrawal of a dopaminergic drug (mainly levodopa) identified a study of 11 cases, which indicated that the patients had an average latency period of 92.72 ± 13.24 hours before developing NMS. 13 Other studies show a similar time to onset. We therefore concluded that there was little possibility that ARP induced the NMS symptoms. Instead, we believe it is likely that LTG caused the NMS symptoms in our patient and therefore recommend the use of caution when administering LTG. 
